TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
30.88
-0.06 (-0.19%)
At close: Feb 21, 2025, 4:00 PM
30.58
-0.30 (-0.96%)
After-hours: Feb 21, 2025, 7:52 PM EST
TG Therapeutics Revenue
TG Therapeutics had revenue of $83.88M in the quarter ending September 30, 2024, a decrease of -49.41%. This brings the company's revenue in the last twelve months to $264.79M, up 39.53% year-over-year. In the year 2023, TG Therapeutics had annual revenue of $233.66M with 8,290.02% growth.
Revenue (ttm)
$264.79M
Revenue Growth
+39.53%
P/S Ratio
16.88
Revenue / Employee
$1,002,992
Employees
264
Market Cap
4.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | 152.00K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TGTX News
- 4 days ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 4 weeks ago - TG Therapeutics: Entering 2025 With Increased Investor Expectations - Seeking Alpha
- 4 weeks ago - TG Therapeutics: 2025 Revenues Will Smash Expectations - Seeking Alpha
- 5 weeks ago - TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst - Seeking Alpha
- 6 weeks ago - TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - 20 stocks likely to lag the S&P 500 over the next year — for this one reason - Market Watch
- 3 months ago - TG Therapeutics to Participate in the Evercore HealthCONx Conference - GlobeNewsWire
- 3 months ago - TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ - GlobeNewsWire